Liquidia Corporation announced that the U.S. Food and Drug Administration granted Fast Track Designation to YUTREPIA (treprostinil) inhalation powder for treating Raynaud's phenomenon associated with systemic sclerosis (SSc-RP). This designation facilitates expedited development and review due to the serious nature of the condition and lack of approved therapies, potentially enabling rolling New Drug Application review. The company plans to initiate the RE-WARM Phase 2a dose-finding study in October 2026 for approximately 75 adults with SSc-RP. Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing products for respiratory and vascular diseases using its proprietary PRINT technology.

Liquidia Corporation reported second quarter 2026 financial results on August 12, 2026. Net product sales for YUTREPIA reached approximately $170.4 million, a 31% increase from the first quarter of 2026. The company recorded net income of $74.7 million and adjusted EBITDA of $96.3 million, marking its fourth consecutive quarter of increasing profitability. Cash and cash equivalents totaled $284.2 million as of June 30, 2026. Since launching in June 2025, YUTREPIA has generated approximately 5,900 unique patient prescriptions and treated more than 5,000 patients. Liquidia Corporation is a biopharmaceutical company developing therapies for respiratory and vascular diseases using its proprietary PRINT technology.

Liquidia Corporation announced that it will be added to the S&P SmallCap 600 Index, effective prior to the opening of trading on June 22, 2026.